Table 2 Patients sub-groups stratification according to staging systems used in our analysis
Staging systems | ||||||
|---|---|---|---|---|---|---|
Patients | General series | TACE exclusive | TACE non exclusive | TACE exclusive lipiodol | TACE exclusive microspheres | |
Score (%) | n = 150 | n = 82 | n = 68 | n = 50 | n = 32 | |
ECOG | 0-1 | 133 (89) | 73 (89) | 60 (88) | 42 (84) | 31 (97) |
2-4 | 17 (11) | 9 (11) | 8 (12) | 8 (16) | 1 (3) | |
TNM | 1-3B | 130 (87) | 72 (88) | 58 (85) | 44 (88) | 28 (87) |
3C-4 | 20 (13) | 10 (12) | 10 (15) | 6 (12) | 4 (13) | |
Child-Pugh | A | 87 (58) | 39 (48) | 48 (70) | 26 (51) | 14 (43) |
B | 63 (42) | 43 (52) | 20 (30) | 24 (49) | 18 (57) | |
CLIP | 0-1 | 92 (61) | 47 (57) | 44 (64) | 29 (58) | 18 (57) |
> 1 | 58 (39) | 35 (43) | 24 (36) | 21 (42) | 14 (43) | |
BCLC | A | 74 (46) | 32 (39) | 41 (61) | 19 (38) | 13 (41) |
B-C | 76 (54) | 50 (61) | 27 (39) | 31 (62) | 19 (59) | |
Okuda | 1 | 98 (65) | 50 (61) | 47 (69) | 31 (62) | 19(60) |
2 | 48 (32) | 27 (33) | 21 (31) | 17 (33) | 11 (33) | |
3 | 4 (3) | 5 (6) | 0 (0) | 2 (5) | 2 (7) | |
JIS | 0-1 | 79 (52) | 37 (45) | 41 (60) | 24 (49) | 13 (40) |
> 1 | 71 (48) | 45 (55) | 27 (40) | 26 (51) | 19 (60) | |
MELD | ≤10 | 101 (67) | 53 (65) | 49 (72) | 32 (64) | 21 (67) |
11-15 | 42 (28) | 25 (30) | 18 (27) | 15 (30) | 9 (29) | |
> 15 | 7 (5) | 4 (5) | 1 (1) | 3 (6) | 2 (4) | |
MELD-Na | ≤10 | 65 (43) | 37 (45) | 39 (57) | 21 (42) | 16 (50) |
11-15 | 58 (39) | 37 (45) | 22 (33) | 22 (45) | 15 (46) | |
> 15 | 27 (18) | 8 (10) | 7 (10) | 7 (13) | 1 (4) | |